Coherus Oncology, Inc.
CHRSHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeCoherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. At a $226.7M market cap, Coherus Oncology, Inc. ranks as a micro-cap company within healthcare. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel next-generation programmed death receptor-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype (IgG1) monoclonal antibody targeting interleukin IL-27.
Market Cap
$226.7M
Beta
0.98
P/E (TTM)
—
P/E (Fwd)
-1.44
EPS (TTM)
$-1.42
EPS (Fwd)
$-1.02
ROE
—
ROA
-32.8%
Cash
$167.0M
Total Debt
$54.4M
Free CF
-$27.1M
52W Change
59.4%
Annual Financials
Cash vs Debt
Where CHRS stands vs its 150-day and 200-day moving averages
As of the July 10, 2026 close, CHRS finished 1.21% below its 150-day moving average ($1.65) and 0.62% above its 200-day moving average ($1.62). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is CHRS overbought or oversold?
At the July 10, 2026 close, CHRS's RSI(14) was 68.8, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Coherus Oncology, Inc. holds $167.0M in cash against $54.4M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow is running at -$27.1M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Revenue has been uneven over recent years, ranging from $211.0M to $42.2M.
With cash comfortably exceeding debt, CHRS has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing CHRS.